Adicet Bio entered the second quarter a clinical-stage company betting everything on a single allogeneic gamma delta T cell therapy, prula-cel (formerly ADI-001), in autoimmune disease - a novel approach that has shown early signs of working, but has not yet proven it. The quarter is best read as a story of discipline and timing rather than progress visible in a total. The company cut second-quarter research and development spending by 35% year over year to $18.5 million, gated new patient enrollment, and ended June with $118.2 million in cash - enough, per management, to fund operations into the second half of 2027.
The headline operating line moved in the right direction even as there is no revenue and no imminent path to it. Net loss narrowed to $21.4 million, or $1.99 per share (GAAP, basic and diluted), from $31.2 million, or $5.48 per share (GAAP), a year earlier. The spend is coming down because the pipeline was reprioritized, not because the lead program stalled: management is conserving capital ahead of its most consequential catalyst since the merger with resTORbio five years ago.
The decision hinge is near-binary, and it sits squarely in the third quarter. Adicet expects to present a Phase 1 update for prula-cel in lupus nephritis and systemic lupus erythematosus - 22 patients with at least six months of follow-up, 13 of them at twelve months or more - and to submit a regulatory filing for its second candidate, ADI-212, in metastatic castration-resistant prostate cancer. Two more data disclosures (systemic sclerosis, rheumatoid arthritis) and an in vivo CAR-T platform update are scheduled for the second half. At roughly $8.23, the market cap of about $85-90 million sits below the $118 million cash balance itself. The stock is priced for the pipeline as near-free option value. What the next three months decide is whether that option is worth exercising.